Merit medical receives fda “breakthrough device designation” for embosphere® microspheres for use in genicular artery embolization for symptomatic knee osteoarthritis

South jordan, utah, march 07, 2022 (globe newswire) -- merit medical systems, inc. (nasdaq: mmsi), announced today that it has received “breakthrough device designation” from the u.s. food & drug administration (fda) for embosphere® microspheres for the genicular artery embolization (gae) indication.
MMSI Ratings Summary
MMSI Quant Ranking